0.31
+0.01(+3.39%)
Currency In USD
| Previous Close | 0.3 |
| Open | 0.33 |
| Day High | 0.46 |
| Day Low | 0.3 |
| 52-Week High | 6.18 |
| 52-Week Low | 0.28 |
| Volume | 48.57M |
| Average Volume | 2.6M |
| Market Cap | 1.54M |
| PE | -0.08 |
| EPS | -3.66 |
| Moving Average 50 Days | 0.59 |
| Moving Average 200 Days | 0.64 |
| Change | 0.01 |
If you invested $1000 in Quoin Pharmaceuticals, Ltd. (QNRX) since IPO date, it would be worth $0.02 as of February 05, 2025 at a share price of $0.305. Whereas If you bought $1000 worth of Quoin Pharmaceuticals, Ltd. (QNRX) shares 5 years ago, it would be worth $0.22 as of February 05, 2025 at a share price of $0.305.
For more details, use our stock calculator to calculate how much you would've made investing different amounts on specific dates.
Quoin Pharmaceuticals Launches ‘NETHERTON NOW’ Campaign to Raise Awareness of Netherton Syndrome, a Rare Genetic Disease with No Approved Treatment or Cure
GlobeNewswire Inc.
Yesterday at 12:30 PM GMT
Multi-pronged media campaign to raise awareness about the disease and its impact on patients, family members and caregivers.Interactive, stand-alone NETHERTON NOW website launched.Quoin’s QRX003 product is on track to obtain the first regulatory appr
Quoin Pharmaceuticals Announces Further Clinical Evidence of QRX003 Effectiveness in Netherton Syndrome
GlobeNewswire Inc.
Jan 23, 2025 1:30 PM GMT
Four Weeks After Discontinuation of Treatment with QRX003 Complete Reversal of Positive Clinical Improvements Across all Measured Endpoints ObservedData Supports QRX003 Mechanism of Action as a Competitive Broad Spectrum Serine Protease Inhibitor ASH
Quoin Pharmaceuticals Announces Further Positive Clinical Data from Ongoing Pediatric Netherton Syndrome Study
GlobeNewswire Inc.
Jan 14, 2025 1:30 PM GMT
Continued Significant Improvement in Skin Appearance Observed in StudySubject’s Disease Classification Improved from “Severe” to “Mild” after 6 Weeks Dosing Treatment area expanded from 20% Body Surface Area to “Whole Body” ASHBURN, Va., Jan. 14, 20